Sarcomatoid hepatocellular carcinoma in a chronic hepatitis B infection patient without previous antitumor therapy: a case report and literature review

Author:

Chen Xiaorong1,Luo Fang1,Zhou Hang2

Affiliation:

1. The First Affiliated Hospital of Chongqing Medical University

2. Jinshan Hospital, The First Affiliated Hospital of Chongqing Medical University

Abstract

Abstract Background Sarcomatoid hepatocellular carcinoma (SHC) is rare. As a subtype of hepatocellular carcinoma (HCC), the clinical manifestations of SHC are similar to those of traditional HCC. Surgical resection is the main treatment, and postoperative adjuvant therapy can prolong the life of patients. However, the prognosis of sarcomatoid hepatocellular carcinoma is worse than that traditional HCC. Case presentation: we report a 69-year-old male patient with sarcomatoid hepatocellular carcinoma who was admitted to the hospital because of liver enlargement. Abdominal computed tomography revealed a mass in the right lobe of the liver (6.8 cm*4.8 cm). After middle hepatectomy, sarcomatous hepatocellular carcinoma was confirmed by histopathology and immunohistochemistry, and the patient was treated with transcatheter arterial chemoembolization(TACE) and targeted drugs after surgery. The patient died 26 months after surgery. Furthermore, we summarized the clinical, pathological, imaging and treatment of this type of tumor to further understand this solid tumor. Conclusion Sarcomatoid hepatocellular carcinoma is a rare subtype of hepatocellular carcinoma, Immunohistopathology is the main way to confirm the diagnosis. Due to the high malignancy and recurrence and metastasis rates of SHC, definite pathological diagnosis, suitable postoperative adjuvant therapy and strict follow-up management are helpful to improve the progression-free survival and survival rate of patients with SHC.

Publisher

Research Square Platform LLC

Reference28 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PMID: 25651787.

2. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019 Sep 28;394(10204):1145–1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24. Erratum in: Lancet. 2020 Jul 4;396(10243):26. PMID: 31248666; PMCID: PMC6891889.

3. Villanueva A, Hepatocellular Carcinoma N, Engl JM. 2019 Apr 11;380(15):1450–1462. doi: 10.1056/NEJMra1713263. PMID: 30970190.

4. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst. 2017 Sep 1;109(9):djx030. doi: 10.1093/jnci/djx030. PMID: 28376154; PMCID: PMC5409140.

5. Nishi H, Taguchi K, Asayama Y, Aishima S, Sugimachi K, Nawata H, Tsuneyoshi M. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol. 2003 Apr;18(4):415 – 23. doi: 10.1046/j.1440-1746.2003.02888. x. PMID: 12653890.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3